New targeted drug hopes to shrink Hard-to-Treat cancers
NCT ID NCT06257264
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 27 times
Summary
This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors (like breast, ovarian, or lung cancer) that haven't responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors, either alone or combined with other drugs. About 258 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Auckland City Hospital
RECRUITINGAuckland, 1023, New Zealand
-
Avera Cancer Institute
RECRUITINGSioux Falls, South Dakota, 57105-2108, United States
-
Beijing Cancer Hospital
RECRUITINGBeijing, Beijing Municipality, 100142, China
-
Blacktown Cancer and Haematology Centre
RECRUITINGBlacktown, New South Wales, NSW 2148, Australia
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
-
Cancer Research South Australia
RECRUITINGAdelaide, South Australia, SA 5000, Australia
-
Florida Cancer Specialists and Research Institute
COMPLETEDLake Mary, Florida, 32746-2115, United States
-
Genesiscare North Shore
RECRUITINGSt Leonards, New South Wales, NSW 2065, Australia
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, 150000, China
-
Hoag Memorial Presbyterian
RECRUITINGNewport Beach, California, 92663-4162, United States
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, 410013, China
-
Mary Crowley Cancer Research
RECRUITINGDallas, Texas, 75230, United States
-
Monash Health
RECRUITINGClayton, Victoria, VIC 3168, Australia
-
Nepean Hospital
RECRUITINGKingswood, New South Wales, NSW 2747, Australia
-
Princess Alexandra Hospital
RECRUITINGWoolloongabba, Queensland, QLD 4102, Australia
-
Rambam Health Care Center
RECRUITINGHaifa, 3109601, Israel
-
Saint Vincents Hospital Sydney
RECRUITINGDarlinghurst, New South Wales, NSW 2010, Australia
-
Shaare Zedek Medical Center
RECRUITINGJerusalem, 9103102, Israel
-
Shengjing Hospital of China Medical Universityhuaxiang Branch
RECRUITINGShenyang, Liaoning, 110022, China
-
Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South)
RECRUITINGGuangzhou, Guangdong, 510245, China
-
The First Affiliated Hospital of Xian Jiaotong University
RECRUITINGXi'an, Shaanxi, 710061, China
-
The Institute of Oncology, Arensia Exploratory Medicine
RECRUITINGChisinau, 2025, Moldova
-
Titan Health Partners Llc Dba Astera Cancer Care
RECRUITINGEast Brunswick, New Jersey, 08816-4096, United States
-
Washington University School of Medicine
RECRUITINGSt Louis, Missouri, 63110-1010, United States
Conditions
Explore the condition pages connected to this study.